Has Alicia Saltzman, APRN received payments from drug or device companies?

Yes. Drug and device makers reported $2,994 in general payments to Alicia Saltzman, APRN across 146 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alicia Saltzman, APRN did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alicia Saltzman, APRN come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alicia Saltzman, APRN

Primary Care · Findlay, OHNPI 1063036580

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,308, 3.3 times the $393 reported in 2022.

$2,994in general payments, 2019–2025

Across 146 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$616
Gilead$363
Madrigal Pharmaceuticals$323
Takeda Pharmaceuticals U.S.A., Inc.$220
Sanofi$199
Aimmune Therapeutics, Inc.$174
plus $1K from 16 others

What the payments were for

Food & beverage$2,97099%
Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	33	$616
Gilead	12	$363
Madrigal Pharmaceuticals	12	$323
Takeda Pharmaceuticals U.S.A., Inc.	13	$220
Sanofi	10	$199
Aimmune Therapeutics, Inc.	12	$174
Viiv Healthcare Company	9	$149
Novo Nordisk	2	$138
Johnson & Johnson	7	$138
Ardelyx, Inc.	5	$122
Phathom Pharmaceuticals, Inc.	8	$108
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$105
Regeneron Healthcare Solutions, Inc.	4	$73
Ferring Pharmaceuticals Inc.	2	$52
Merck	2	$51
Organon	2	$34
Lilly USA, LLC	2	$28
Bristol Myers Squibb	1	$25
Mylan Institutional Inc.	1	$24
Celltrion USA Inc.	1	$24
Ipsen Biopharmaceuticals, Inc	1	$15
Insmed, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,994 in reported general payments places this provider in the 85th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio →

Medicare billing

Part B allowed, 2024

$57,322

Medicare patients

276

Services billed

659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Vancomycin Hcl	24	$5,289
CeftriaxoneCeftriaxone Sodium	24	$3,845
Pantoprazole Sodium	132	$1,852
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	19	$1,248
Sucralfate	22	$1,069
Omeprazole	69	$906
Lactulose	17	$484
Esomeprazole Magnesium	13	$385
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	20	$258
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl	14	$191
Doxycycline Hyclate	13	$182
Spironolactone	14	$132

Paid to pharmacies, not to this prescriber.

Other primary care in Findlay

Regan HeagenFindlay$8K
Kendal LillyFindlay$4K
Adine EdwardsSpringfield$14K
Kelly McKenna TaulbeeHamilton$12K
Lindsay ChappellFairlawn$11K
Laura HolligerNorth Canton$10K
Caitlyn FrantzDayton$10K
Brandy RichardsCleveland$8K
Zachary HaleBeavercreek$7K
Katherine ElliotWesterville$7K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →